Liping Zuo

931 total citations
26 papers, 721 citations indexed

About

Liping Zuo is a scholar working on Molecular Biology, Biomedical Engineering and Oncology. According to data from OpenAlex, Liping Zuo has authored 26 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Biomedical Engineering and 6 papers in Oncology. Recurrent topics in Liping Zuo's work include Nanoplatforms for cancer theranostics (7 papers), Peptidase Inhibition and Analysis (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Liping Zuo is often cited by papers focused on Nanoplatforms for cancer theranostics (7 papers), Peptidase Inhibition and Analysis (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Liping Zuo collaborates with scholars based in China, Ethiopia and United States. Liping Zuo's co-authors include Hai‐Yan Xie, Weidong Nie, Lili Huang, Wei Wei, Wan‐Ru Zhuang, Guanghao Wu, Peilin Wang, Lei Yao, Xiaoyong Gao and Jin Xu and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Communications and Nano Letters.

In The Last Decade

Liping Zuo

21 papers receiving 713 citations

Peers

Liping Zuo
Ruiqing He China
Zhipeng Zhao China
Jinhyang Choi South Korea
Tongren Yang China
Na Kyeong Lee South Korea
Kai Kraemer Germany
Alessio Malfanti Italy
Huizi Sha China
Ruiqing He China
Liping Zuo
Citations per year, relative to Liping Zuo Liping Zuo (= 1×) peers Ruiqing He

Countries citing papers authored by Liping Zuo

Since Specialization
Citations

This map shows the geographic impact of Liping Zuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liping Zuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liping Zuo more than expected).

Fields of papers citing papers by Liping Zuo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liping Zuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liping Zuo. The network helps show where Liping Zuo may publish in the future.

Co-authorship network of co-authors of Liping Zuo

This figure shows the co-authorship network connecting the top 25 collaborators of Liping Zuo. A scholar is included among the top collaborators of Liping Zuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liping Zuo. Liping Zuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Chi, Aoshuang Xu, Liping Zuo, et al.. (2025). Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential. Pharmaceuticals. 18(5). 640–640.
2.
3.
Wang, Xuezhu, Liping Zuo, Jian Xu, et al.. (2025). Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis. Genomics Proteomics & Bioinformatics. 23(2).
4.
Zuo, Liping & Kuikun Yang. (2025). Cyclodextrin-based supramolecular polymers based on host–guest interactions for cancer therapy. 2(4). 100044–100044. 1 indexed citations
5.
Zuo, Liping, Guangqi Wang, Qun Li, et al.. (2025). T Cells Dysfunction in Multiple Myeloma. ImmunoTargets and Therapy. Volume 14. 997–1014.
6.
Zuo, Liping, Zhixin Li, Li Cai, et al.. (2025). LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma. Haematologica. 110(11). 2779–2785.
7.
Li, Qun, Lisha Ai, Liping Zuo, et al.. (2024). Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis. Annals of Medicine. 56(1). 2338604–2338604. 6 indexed citations
8.
Li, Qun, Chi Ma, Liping Zuo, et al.. (2024). Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma. Blood. 144(Supplement 1). 4659–4659. 1 indexed citations
9.
Zhang, Jiasi, Yuxi Liu, Liping Zuo, et al.. (2024). Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma. Blood Advances. 8(19). 5022–5038. 6 indexed citations
10.
Zhang, Jiasi, Yuxi Liu, Qun Li, et al.. (2023). ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis. Carcinogenesis. 44(3). 242–251. 22 indexed citations
11.
Gao, Su, Aoshuang Xu, Liping Zuo, et al.. (2023). MALAT1 regulates network of microRNA-15a/16–VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma. Carcinogenesis. 44(10-11). 760–772. 9 indexed citations
12.
Zhuang, Wan‐Ru, Yunfeng Wang, Weidong Nie, et al.. (2023). Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity. Nature Communications. 14(1). 1675–1675. 78 indexed citations
13.
Xu, Aoshuang, Jiasi Zhang, Liping Zuo, et al.. (2021). FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. Molecular Therapy. 30(3). 1104–1118. 50 indexed citations
14.
Song, Jinjin, Yaying Ma, Liyuan Yang, et al.. (2021). Auxin and cytokinin mediated regulation involved in vitro organogenesis of papaya. Journal of Plant Physiology. 260. 153405–153405. 11 indexed citations
15.
Zuo, Liping, Weidong Nie, Wan‐Ru Zhuang, et al.. (2021). Smart Tumor‐Cell‐Derived Microparticles Provide On‐Demand Photosensitizer Synthesis and Hypoxia Relief for Photodynamic Therapy. Angewandte Chemie International Edition. 60(48). 25365–25371. 52 indexed citations
16.
Lu, Guihong, Liping Zuo, Jinfeng Zhang, et al.. (2020). Two-step tumor-targeting therapy via integrating metabolic lipid-engineering with in situ click chemistry. Biomaterials Science. 8(8). 2283–2288. 16 indexed citations
17.
Yang, Wei, Liping Zuo, Xinru Li, et al.. (2020). OsHsfB4d Binds the Promoter and Regulates the Expression of OsHsp18.0-CI to Resistant Against Xanthomonas Oryzae. Rice. 13(1). 28–28. 27 indexed citations
18.
Wu, Guanghao, Wei Wei, Jinfeng Zhang, et al.. (2020). A self-driven bioinspired nanovehicle by leukocyte membrane-hitchhiking for early detection and treatment of atherosclerosis. Biomaterials. 250. 119963–119963. 72 indexed citations
19.
Xu, Aoshuang, Jiasi Zhang, Liping Zuo, et al.. (2019). Fto Promotes Extramedullary Progression of Multiple Myeloma By Regulation of HSF1 through m6a RNA Methylation. Blood. 134(Supplement_1). 3063–3063. 2 indexed citations
20.
Zhang, Ruihua, et al.. (2017). Overexpression of OsHSP18.0-CI Enhances Resistance to Bacterial Leaf Streak in Rice. Rice. 10(1). 12–12. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruiqing He Breakdown of academic impact, for papers by Zhipeng Zhao Breakdown of academic impact, for papers by Jinhyang Choi Breakdown of academic impact, for papers by Tongren Yang Breakdown of academic impact, for papers by Na Kyeong Lee Breakdown of academic impact, for papers by Kai Kraemer Breakdown of academic impact, for papers by Alessio Malfanti Breakdown of academic impact, for papers by Huizi Sha
Rankless by CCL
2026